Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis

Liu,Fu-Yao; Wu,Yan-Hui; Zhou,Shao-Jun; Deng,Yue-Ling; Zhang,Zun‑Yi; Zhang,Er-Lei; Huang,Zhi-Yong

doi:10.3892/or.2014.3248

Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis

Authors:
- Fu-Yao Liu
- Yan-Hui Wu
- Shao-Jun Zhou
- Yue-Ling Deng
- Zun‑Yi Zhang
- Er-Lei Zhang
- Zhi-Yong Huang
View Affiliations

Affiliations: Research Laboratory and Hepatic Surgical Center, Department of Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China, Department of Gastroenterology, Mianyang Center Hospital, Mianyang, Sichuan, P.R. China
Published online on: June 12, 2014 https://doi.org/10.3892/or.2014.3248
Pages: 835-844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Minocycline, a semisynthetic tetracycline, is a highly lipophilic molecule capable of infiltrating tissues and blood. Previous studies have revealed the functions and mechanisms of minocycline in anti-inflammation, protection of the nervous system and certain tumors. The role of minocycline has never been investigated in hepatocellular carcinoma (HCC). The functions of minocycline on HCC cells were investigated using immunohistochemical staining and western blotting. Minocycline was applied to L02, HepG2 and Huh7 cells, and the growth characteristics were studied. Cisplatin was administered in combination with minocycline in this study. Cell cycle and apoptosis analyses were employed to investigate the mechanisms underlying the growth regulation associated with minocycline and(or) cisplatin. Minocycline caused S phase cell cycle arrest and an increase in the apoptotic rate associated with upregulation of p27, cleaved-caspase8, cleaved-caspase3 and cleaved-PRAP-1. Low dose of cisplatin promoted cell cycle arrest and apoptosis, whereas minocycline was mainly associated with upregulation of cleaved-PARP-1. The combination of cisplatin and minocycline increased the rate and extent of cell cycle arrest and increased the apoptosis rate caused by minocycline. A novel mechanism was revealed. Minocycline functions as an antitumor drug in HCC by regulating p27, caspase-3 and PARP-1. Cisplatin enhanced minocycline's effect on PARP-1.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Yoshimoto S, Loo TM, Atarashi K, et al: Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 499:97–101. 2013. View Article : Google Scholar : PubMed/NCBI
3	Min L, Ji Y, Bakiri L, et al: Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol. 14:1203–1211. 2012. View Article : Google Scholar : PubMed/NCBI
4	Xu X, Fan Z, Kang L, et al: Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 123:630–645. 2013.PubMed/NCBI
5	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
7	Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao YF and Huang ZY: PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells. Oncol Rep. 20:567–572. 2008.PubMed/NCBI
8	Yu S-W, Wang H, Poitras MF, et al: Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 297:259–263. 2002. View Article : Google Scholar : PubMed/NCBI
9	Alano CC, Kauppinen TM, Valls AV and Swanson RA: Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA. 103:9685–9690. 2006. View Article : Google Scholar : PubMed/NCBI
10	Yong VW, Wells J, Giuliani F, Casha S, Power C and Metz LM: The promise of minocycline in neurology. Lancet Neurol. 3:744–751. 2004. View Article : Google Scholar : PubMed/NCBI
11	Le CH, Morales A and Trentham DE: Minocycline in early diffuse scleroderma. Lancet. 352:1755–1756. 1998. View Article : Google Scholar : PubMed/NCBI
12	Zhu S, Stavrovskaya IG, Drozda M, et al: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 417:74–78. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zink MC, Uhrlaub J, DeWitt J, et al: Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 293:2003–2011. 2005. View Article : Google Scholar : PubMed/NCBI
14	Stefanova N, Bücke P, Duerr S and Wenning GK: Multiple system atrophy: an update. Lancet Neurol. 8:1172–1178. 2009. View Article : Google Scholar : PubMed/NCBI
15	Pourgholami MH, Ataie-Kachoie P, Badar S and Morris DL: Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. Gynecol Oncol. 129:113–119. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bouwman P and Jonkers J: The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
17	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
18	Fuertes MA, Alonso C and Pérez JM: Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chemical Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005. View Article : Google Scholar : PubMed/NCBI
20	Haubrich WS: Apoptosis. Gastroenterology. 119:18052000. View Article : Google Scholar
21	Lord CJ and Ashworth A: The DNA damage response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
22	Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
23	Nakayama K, Nagahama H, Minamishima YA, et al: Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19:2069–2081. 2000. View Article : Google Scholar : PubMed/NCBI
24	le Sage C, Nagel R, Egan DA, et al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708. 2007.PubMed/NCBI
25	Penninger JM and Kroemer G: Mitochondria, AIF and caspases - rivaling for cell death execution. Nat Cell Biol. 5:97–99. 2003. View Article : Google Scholar : PubMed/NCBI
26	Virag L, Robaszkiewicz A, Vargas JM and Oliver FJ: Poly(ADP-ribose) signaling in cell death. Mol Aspects Med. 34:1153–1167. 2013. View Article : Google Scholar : PubMed/NCBI
27	Günther C, Martini E, Wittkopf N, et al: Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature. 477:335–339. 2011.PubMed/NCBI
28	Jin Z, Li Y, Pitti R, et al: Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 137:721–735. 2009. View Article : Google Scholar : PubMed/NCBI
29	Stilmann M, Hinz M, Arslan SÇ, Zimmer A, Schreiber V and Scheidereit C: A nuclear poly(ADP-Ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell. 36:365–378. 2009. View Article : Google Scholar : PubMed/NCBI
30	Midorikawa R, Takei Y and Hirokawa N: KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity. Cell. 125:371–383. 2006. View Article : Google Scholar : PubMed/NCBI
31	Vondálová Blanárová O, Jelinková I, Szöor A, et al: Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis. 32:42–51. 2011.PubMed/NCBI
32	Barton C, Davies D, Balkwill F and Burke F: Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer. 41:1474–1486. 2005. View Article : Google Scholar : PubMed/NCBI
33	Qin LF and Ng IO: Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett. 175:27–38. 2002. View Article : Google Scholar : PubMed/NCBI
34	Liu FY, Deng YL, Li Y, et al: Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol. 30:4252013. View Article : Google Scholar : PubMed/NCBI